Welireg (belzutifan) / Merck (MSD)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

14 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Welireg (belzutifan) / Merck (MSD)
2020-005007-40: A clinical trial to investigate the safety and efficacy of 3 drug treatments when they are used to treat solid gastric tumors.

Not yet recruiting
2
400
Europe
Belzutifan, Lenvatinib, MK-6482, E7080, Film-coated tablet, Solution for infusion, Capsule, hard, KEYTRUDA(pembrolizumab,MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
HCC, non-microsatellite instability-high (MSI-H)/ deficient mismatch repair (dMMR) CRC, PDAC, and BTC, Liver cancer; Colon cancer; Pancreatic cancer; or Biliary Tract cancer, Diseases [C] - Cancer [C04]
 
 
LITESPARK-013, NCT04489771 / 2020-001907-18: A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

Active, not recruiting
2
154
Europe, US, RoW
Belzutifan, MK-6482, PT2977, WELIREG™
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
02/23
10/25
LITESPARK-029, NCT06428396: Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/)

Not yet recruiting
2
120
NA
Belzutifan, MK-6482, Fulvestrant, Everolimus, Exemestane
Merck Sharp & Dohme LLC
Metastatic Breast Cancer
06/27
05/28
J2258, NCT05574712: A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer

Withdrawn
2
30
NA
Neoadjuvant treatment, leuprolide acetate, abiraterone acetate, belzutifan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
01/25
07/26
LITESPARK-003, NCT03634540: A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Checkmark Cohort 1 data of LITESPARK-003 trial in combination with Cabometyx for treatment-naïve advanced RCC
Sep 2022 - Sep 2022: Cohort 1 data of LITESPARK-003 trial in combination with Cabometyx for treatment-naïve advanced RCC
Checkmark Cohort 2 data of LITESPARK-003 trial in combination with Cabometyx for treatment-naïve advanced RCC
Sep 2022 - Sep 2022: Cohort 2 data of LITESPARK-003 trial in combination with Cabometyx for treatment-naïve advanced RCC
Active, not recruiting
2
118
US
Belzutifan, PT2977, MK-6482, WELIREG™, Cabozantinib, CABOMETYX®
Peloton Therapeutics, Inc.
Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
08/25
08/25
LITESPARK-004, NCT03401788 / 2018-000125-30: A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

Checkmark Updated data from trial for Von Hippel Lindau at ASCO 2021
Jun 2021 - Jun 2021: Updated data from trial for Von Hippel Lindau at ASCO 2021
Checkmark Updated data from trial for Von Hippel Lindau disease-associated renal cell carcinoma at ESMO 2020
Sep 2020 - Sep 2020: Updated data from trial for Von Hippel Lindau disease-associated renal cell carcinoma at ESMO 2020
Checkmark Data from trial for Von-hippel lindau disease associated RCC
More
Active, not recruiting
2
50
Europe, US
Belzutifan, PT2977, MK-6482, WELIREG™
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation, VHL-Associated Renal Cell Carcinoma, VHL-Associated Clear Cell Renal Cell Carcinoma
03/26
03/26
LITESPARK-016, NCT04976634: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Recruiting
2
730
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Belzutifan, MK-6482, PT2977, WELIREG™, Lenvatinib, MK-7902, E7080, LENVIMA®
Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma, Biliary Tract Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms
03/27
03/27
MK-6482-015, NCT04924075 / 2020-005028-13: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations

Recruiting
2
322
Europe, Canada, Japan, US, RoW
Belzutifan, MK-6482, WELIREG™
Merck Sharp & Dohme LLC
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
02/27
02/27
2019-003610-13: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03B

Not yet recruiting
1/2
370
Europe
Lenvatinib, MK-1308/Pembrolizumab, MK-4280/Pembrolizumab, MK-4830, MK-6482, E7080, MK-1308A, MK-4280A, MK-4830, MK-6482, Solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Renal Cell Carcinoma (Kidney Cancer), Diseases [C] - Cancer [C04]
 
 
2019-003609-84: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03A

Not yet recruiting
1/2
430
Europe
Lenvatinib, MK-1308/Pembrolizumab, MK-4280/Pembrolizumab, MK-6482, E7080, MK-1308A, MK-4280A, MK-6482, Solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Renal Cell Carcinoma (Kidney Cancer), Diseases [C] - Cancer [C04]
 
 
KEYMAKER-U03B, NCT04626518: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Active, not recruiting
1/2
370
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, MK-4830, Belzutifan, MK-6482, WELIREG™, Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab/Quavonlimab, MK-1308A, Favezelimab/Pembrolizumab, MK-4280A
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
09/25
09/25
MK-3475-03A, NCT04626479: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma

Active, not recruiting
1/2
400
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Favezelimab/Pembrolizumab, MK-4280A, Belzutifan, MK-6482, WELIREG™, Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab/Quavonlimab, MK-1308A, Vibostolimab/Pembrolizumab, MK-7684A
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
05/26
05/26
LITESPARK-024, NCT05468697: A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/)

Recruiting
1/2
180
US, RoW
Belzutifan, WELIREG™, MK-6482, PT2977, Palbociclib, IBRANCE®, PD 0332991
Merck Sharp & Dohme LLC
Renal Cell Carcinoma
03/27
03/27
KEYNOTE-365, NCT02861573 / 2016-002312-41: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/)

Checkmark 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Sep 2022 - Sep 2022: 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Recruiting
1/2
1200
Europe, Canada, US, RoW
Pembrolizumab 200 mg, KEYTRUDA®, MK-3475, Olaparib 400 mg, LYNPARZA®, MK-7339, Docetaxel 75 mg/m^2, TAXOTERE®, Prednisone 5 mg, Enzalutamide 160 mg, XTANDI®, Dexamethasone 8 mg, Olaparib 300 mg, Abiraterone acetate 1000 mg, ZYTIGA®, Lenvatinib, LENVIMA®, MK-7902, Pembrolizumab/Vibostolimab coformulation, MK-7684A, Carboplatin, PARAPLATIN®, Etoposide, TOPOSAR™, Belzutifan 120mg, WELIREG™
Merck Sharp & Dohme LLC
Metastatic Castration-Resistant Prostate Cancer
10/27
10/27

Download Options